CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration - Wikidata - wikimedia - TriplyDB

CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

http://www.wikidata.org/entity/Q35140894

about

Vascular endothelial growth factor genetic polymorphisms and susceptibility to age-related macular degeneration in Tunisian population.VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients Association of PEDF polymorphisms with age-related macular degeneration and polypoidal choroidal vasculopathy: a systematic review and meta-analysis.Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome A Validated Phenotyping Algorithm for Genetic Association Studies in Age-related Macular Degeneration.Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Mechanism of inflammation in age-related macular degeneration Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab.Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.Vascular endothelial growth factor gene polymorphisms and association with age related macular degeneration in Indian patients.CFH Y402H polymorphism and response to intravitreal ranibizumab in Brazilian patients with neovascular age-related macular degeneration.A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Prognostic phenotypic and genotypic factors associated with photodynamic therapy response in patients with age-related macular degeneration.VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.

P2860

Q34092050-EB6B5161-FE12-4BA8-9A06-320F6B3F9CC2 Q34170457-E69F951C-667C-4D79-AF68-EB08CF0E52E0 Q34384420-42DE7174-1352-456C-8299-F9B36F551D48 Q34781693-8A40F5CC-5B1B-4117-A2D3-BD958E2877A5 Q35227249-6DA26F00-1057-446C-8F58-4BC374496359 Q35503206-2FD908E5-BCCE-4679-9D7D-4F87A5509BD4 Q35932943-5C9F865A-4704-4606-8CF3-AEDF02077AF9 Q37166529-C4325528-C1DC-4869-A586-E1DE5340D6D3 Q37232214-C9680816-0531-49F1-9CC3-632B88E3CCC4 Q38030051-CD1B64DF-049F-413F-8F6F-1F701FEF9D7E Q38064846-62276767-22AC-42B4-94A9-26209ED239B0 Q38134807-505AA2E4-189D-42B7-A842-76414AC6C1F5 Q38827325-F20FD6AF-A0DE-4E7F-A702-C82169B2478A Q40982952-0EDA450C-278D-4C30-8D9E-799B7AE9682F Q41289450-F1BB9CA7-6673-4BAB-ACA1-FD89752D666E Q41504310-004CEDDB-BCC6-4677-B815-1BA3896BC900 Q41995683-8C2044D1-F1F0-4221-8762-A748E8D9B49A Q44857733-DFCDA063-3C19-420D-B323-EB77A8DE3487 Q47961971-C6DEB78C-6B58-4E39-BFEF-98E749A603B6 Q52559837-B98491BE-523F-4C94-9F7A-1759F4189E5A

P2860

CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

http://www.wikidata.org/entity/Q35140894

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

CFH, VEGF, and PEDF genotypes ...... e-related macular degeneration

@ast

CFH, VEGF, and PEDF genotypes ...... e-related macular degeneration

@en

type

label

CFH, VEGF, and PEDF genotypes ...... e-related macular degeneration

@ast

CFH, VEGF, and PEDF genotypes ...... e-related macular degeneration

@en

prefLabel

CFH, VEGF, and PEDF genotypes ...... e-related macular degeneration

@ast

CFH, VEGF, and PEDF genotypes ...... e-related macular degeneration

@en

P1433

Q35140894-503133A3-60C2-4E2F-A743-175AB97E19B0

P1476

Q35140894-BB1DFE11-D1E9-4282-AD0C-6E05207CA6E2

P2093

Q35140894-15044A13-A733-4536-AA8F-DDC163659AF9

Q35140894-9D6B9E2C-D369-4F18-86CC-47833338B0D2

Q35140894-A9F37E68-5B48-40BB-809B-F16427DD4139

Q35140894-AB5054F8-99CD-4596-82E7-85A43C44FE86

Q35140894-AF492FF0-D01C-42BE-8702-CFD295C062EF

Q35140894-B6722759-4291-4906-BE18-CAE3C8F0201E

Q35140894-B95FD6FA-9BBD-418D-8E76-9505DCBB34BC

P2860

Q35140894-10165B87-96B4-4F4F-B81F-7F24989ADB30

Q35140894-1EE0ACC6-5E36-4D8F-BC03-55BE08CDDBD6

Q35140894-1EE39A47-E209-4E13-8783-8B003D5B8E22

Q35140894-2236F218-A554-4DDE-BDEE-06D2C198CCE7

Q35140894-2531B280-E412-42F3-A6B7-E8F1F00395A2

Q35140894-2DBB1842-5816-45F6-8A90-0A7AC5910F64

Q35140894-380B6293-A1A2-4814-91F1-331BDA3234E1

Q35140894-3D75D85D-1560-4C97-AA3F-B93F342B6724

Q35140894-3F354260-1EBF-4F6E-9B35-659E0A730651

Q35140894-42841969-5569-43A1-BE4E-73301C1FA227

P2888

Q35140894-4E7DF0D1-5C6C-4680-BC38-057D09C9C08E

P304

Q35140894-94E9245E-8E1C-4571-8C75-099038760CFB

P31

Q35140894-AE93860E-6A3B-41DF-ADED-4D035DA08C83

P356

Q35140894-35335AF0-7062-49FD-A9D5-1160CED1754C

P433

Q35140894-FD6B8D29-6649-4429-8607-50DD086A16B7

P478

Q35140894-671D95A9-B2E9-4515-82F7-713176BF8BBC

P577

Q35140894-D46E2C5D-165A-4B57-B421-7FE726330B17

P5875

Q35140894-E492A2CD-ABE5-4496-98CE-C387321BBE06

P698

Q35140894-259ED7E1-83E8-4DCF-BF1D-F8A1592F209B

P921

Q35140894-B95EBA89-CC69-4145-B3E8-98292B6FBDB4

P932

Q35140894-BA66EDFD-4CD7-4486-B227-DB6B69318FB5

P356

S12177-010-9055-1

P1433

Journal of ocular biology, diseases, and informatics

P1476

CFH, VEGF, and PEDF genotypes ...... e-related macular degeneration

@en

P2093

Daisuke Imai

http://www.w3.org/2001/XMLSchema#string

Keisuke Mori

http://www.w3.org/2001/XMLSchema#string

Kuniko Horie-Inoue

http://www.w3.org/2001/XMLSchema#string

Peter L Gehlbach

http://www.w3.org/2001/XMLSchema#string

Satoshi Inoue

http://www.w3.org/2001/XMLSchema#string

Shin Yoneya

http://www.w3.org/2001/XMLSchema#string

Takuya Awata

http://www.w3.org/2001/XMLSchema#string

P2860

Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration

Susceptibility genes for age-related maculopathy on chromosome 10q26.

Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3

Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration

Complement factor H polymorphism in age-related macular degeneration

Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19

CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration

A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration

Pigment epithelium-derived factor: a potent inhibitor of angiogenesis

P2888

s12177-010-9055-1

P304

53-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12177-010-9055-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51542625

http://www.w3.org/2001/XMLSchema#string

P698

21811649

http://www.w3.org/2001/XMLSchema#string

P921

P932

3148139

http://www.w3.org/2001/XMLSchema#string